University of Erlangen-Nürnberg Medical School

fau.de

Total trials

269

Active

46

Phase 3

43

Total enrollment

55,374

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Dapagliflozin 10mg Tab1
Three intra-articular hyaluronic acid (HA) injections1
One intra-articular hyaluronic acid (HA)1
Chemotherapy 5-Fluorouracil1
Chemotherapy Cisplatin1
Additional interventional telemedical management1
Cisplatin1

Next readouts

  • 2026-04-30
  • 2026-08-01
  • 2026-10-31
  • 2094-12-31
  • 2098-12-31

Top conditions

  • Ulcerative Colitis10
  • Hypertension10
  • Metabolic Syndrome7
  • Cancer7
  • Inflammatory Bowel Diseases6
  • Rheumatoid Arthritis5
  • Osteopenia5
  • Crohn's Disease5

Frequently asked questions about University of Erlangen-Nürnberg Medical School

How many clinical trials does University of Erlangen-Nürnberg Medical School have on ClinicalTrials.gov?
University of Erlangen-Nürnberg Medical School is listed as the lead sponsor on 269 clinical trials in ClinicalTrials.gov, 46 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Erlangen-Nürnberg Medical School's trials are in Phase 3?
43 of University of Erlangen-Nürnberg Medical School's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does University of Erlangen-Nürnberg Medical School focus on?
University of Erlangen-Nürnberg Medical School's most-studied conditions on ClinicalTrials.gov are Ulcerative Colitis, Hypertension, Metabolic Syndrome, Cancer, Inflammatory Bowel Diseases.
When are University of Erlangen-Nürnberg Medical School's next clinical trial readouts?
University of Erlangen-Nürnberg Medical School has 5 upcoming primary-completion readouts tracked here; the soonest is “The smartNTx Trial:Telemedical Management Versus Standard Aftercare in Kidney Transplant Recipients (KTR)”, expected around 2026-04-30.